Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

RAPT Therapeutics Earnings Perspective: Return On Capital Employed

Benzinga Pro data, RAPT Therapeutics (NASDAQ:RAPT) reported Q1 sales of $641.00 thousand. Earnings fell to a loss of $20.47 million, resulting in a 14.16% decrease from last quarter. In Q4, RAPT Therapeutics brought in $756.00 thousand in sales but lost $17.93 million in earnings.

Why Is ROCE Significant?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.